Ground News

institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

CN Bio Innovations image

News from CN Bio Innovations

See all of CN Bio Innovations news coverage in one place. Discover how CN Bio Innovations’s media bias informs their coverage and compare with thousands of other news outlets.

We’ve aggregated 6 of CN Bio Innovations’s headlines and news stories over the past 3 months.

We’ve assigned a media bias rating of unknown to CN Bio Innovations. You can read more about our methodology here.

CN Bio Innovations’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about CN Bio Innovations

Where is CN Bio Innovations located?CN Bio Innovations's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top CN Bio Innovations News

CN Bio joins 3RsC & FDA Liver MPS DILI project

Innovation · Silver Spring

CN Bio joins 3RsC & FDA Liver MPS DILI project

Building Confidence in MPS for Regulatory Applications! At the intersection of innovation, collaboration, and science lies an exciting new project led by the 3Rs Collaborative (3RsC) – and CN Bio is one of the collaborators. This effort brings together regulators, technology providers, end-users, and non-profits to advance the responsible use of microphysiological systems (MPS) in regulatory applications. In partnership with 3RsC, the FDA Cente…Read Article

Microphysiological systems for mAbs development

Welcome to part two of our blog series exploring the FDA’s announcement to phase out the animal testing requirement for monoclonal antibodies (mAbs), and other drugs, in favor of human-relevant new approach methodologies (NAMs). In part one of the blog, we unpicked the reasons behind the FDA’s decision to focus on mAbs first, and steps to ensure that a NAM-based approach will offer the same degree of safety as animals before their use is phased …United States · United States Read Article

CN Bio and Pharmaron Establish Long-Term Strategic Partnership to Develop OOC Technologies on a Global R&D Platform

100% Center coverage: 2 sources

CAMBRIDGE, England--(BUSINESS WIRE)--Apr 23, 2025-England · England See the Story

You've scrolled to the bottom of the feed, there are no more stories.